China Regenerative Medicine Intl : Financial Secretary of HK SAR Paul Chan Mo-po Leads Delegation on Visit to the Group Encourages to Promote the Innovative Technology Development of Regenerative Medicine

[Group News] China Regenerative Medicine International Limited (Stock Code: 8158.HK) Financial Secretary of HK SAR Paul Chan Mo-po Leads Delegation on Visit to the Group Encourages to Promote the Innovative Technology Development of Regenerative Medicine

Hong Kong, 19 Jul 2017 - China Regenerative Medicine International Limited ("China Regenerative Medicine" or "the Company", stock code: 8158.HK, together with its subsidiaries, collectively "the Group") is pleased to announce that Mr. Paul Chan Mo-po, Financial Secretary of Hong Kong SAR led the delegation on visit to the BioCell Technology Limited (previously named "China Stem Cell Clinical Applications Centre") at Hong Kong Science Park, which is affiliated to the Group, to understand Hong Kong's present development of regenerative medicine including cellular and gene products preparation, and encourage the future development of the Group.

Financial Secretary Paul Chan Mo-po and the delegation visited BioCell Technology Limited to gain a better understanding of the development of the Group's cell preparation and storage centre. Mr. Cui Zhanfeng, the Group's Chairman of Board of Directors and Fellow of the Royal Academy of Engineering (FREng) introduced that the centre is built with an investment of over HKD100 million and a total gross floor area of over 2,000 sq.m. It complies with EMA, FDA, CFDA, TGA and GMP/ S standards. It is not only equipped with state-of-the-art cell preparation techniques and instruments, but also operates in strict compliance with a high standard preparation process, striving to becoming an unprecedented international cell and gene manufacturing centre in Asia.

Financial Secretary Paul Chan Mo-po said during the visit, "Hong Kong, being the global financial centre and important transportation hub in Asia, has created a unique favourable environment for the business development of China Regenerative Medicine International Limited. The Hong Kong government has actively developed the innovative industry, and with support of the central government for the full promotion of Guangdong-Hong Kong-Macao Bay Area policy in the future, it is believed that the enterprises will be encouraged to cultivate the aura of innovation which will foster the overall development of the group."

Delegation including Mr. James Lau, Secretary for Financial Services and the Treasury, Mr. Nicholas W Yang, Secretary for Innovation and Technology, Ms. Annie Choi Suk-han, Commissioner for Innovation and Technology, Mrs. Fanny Law, Chairman of the Board of Directors of Hong Kong Science and Technology Parks Corporation, Mr. Albert Wong Hak- keung, CEO of Hong Kong Science and Technology Parks Corporation visited the Group together.

Financial Secretary of HK SAR Paul Chan Mo-po leads the delegation on visit to the BioCell Technology Limited,

affiliated to China Regenerative Medicine International Limited

Mr. Chen Chunguo, CEO of China Regenerative Medicine International Limited said, "Continuous breakthroughs have been made in the current stem cell therapy and drawn high attention worldwide. Experts from different sector are also committed to conducting research on related studies which are put into practice gradually. China has also kept pace with the world and seized the opportunities to conduct stem cell research. President Xi Jinping recently has mentioned in the commentary on how basic scientific breakthroughs including stem cells have made enormous contributions to China's economy. Regenerative medicine, being the leading innovative technology industry, has gained widespread international attention and development. The group deploys its headquarter in Hong Kong to build Hong Kong into an Asian and a global cellular therapy and regenerative medicine applications centre and create value to human well-being with innovative technologies.

China Stem Cell Clinical Applications Centre, located at Hong Kong Science Park, is another modern cell preparation and storage centre that meets GMP standards following those in Suzhou, Tianjin and Changzhou, China. With an investment over HKD100 million, the centre has a gross floor area of more than 2,000 sq.m and complies with EMA, FDA, CFDA, TGA and GMP/ S standards. It is not only equipped with state-of-the-art cell preparation techniques and instruments, but also operates in strict compliance with a high standard preparation process, striving to becoming an unprecedented international cell and gene manufacturing centre in Asia. It will provide international biotech companies, international pharmaceutical companies, clinical application institutions, cell banks and other institutions with technical facilities that meet international and domestic preparation quality criteria as well as technical platforms for clinical application transformation. Meanwhile, it has also built

close partnership relationships with research institutions such as Versitech Limited and University of Oxford together with experts in the field to further consolidate the clinical transformation and commercialization of stem cell and cellular therapy, as well as laid a good foundation for the improvement and development of cell product preparation in the Asia- pacific Region.

Financial Secretary of HK SAR Paul Chan Mo-po (first left) listens to the introduction by China Regenerative Medicine at the "China Stem Cell Clinical Applications Centre" located at Hong Kong Science Park

- End -

About China Regenerative Medicine International Limited

China Regenerative Medicine International Limited, listed on the GEM Board of The Stock Exchange, stock code :8158. China Regenerative Medicine is a high-end new-technology enterprise, principally engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The Group has successfully evolved into a tissue engineering pioneer and has successfully industrialized regenerative medicine, as well as accomplished the research and development and commercialization platform of tissue engineering. The Group has applied for more than 140 domestic and overseas patents on three major business segments, namely tissue engineering, cell therapy, and cosmetics, including 'ActivSkin', the only tissue-engineered skin developed in China, and 'Acornea', the world's first bio-engineered cornea which completed its clinical trials. For more details, please visit www.crmi.hk.

About China Stem Cell Clinical Applications Centre

China Stem Cell Clinical Applications Centre, affiliated to BioCell Technology Limited, a

subsidiary of China Regenerative Medicine International Limited, is located at Hong Kong Science Park. It is a modern cell preparation and storage centre that meets GMP standards following those in Suzhou, Tianjin and Changzhou. With an investment of approximately HKD130 million, the China Stem Cell Clinical Applications Centre has a gross floor area of more than 2,000 sq.m and complies with EMA, FDA, CFDA, TGA and GMP/PIC/S standards. It is not only equipped with state-of-the-art cell preparation techniques and instruments, but also operates in strict compliance with a high standard preparation process.